Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
Organon & Co. (OGN)
Company Research
Source: Business Wire
Collaboration continues to expand portfolio in women’s health to help address unmet needs JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agreement for a novel investigational non-hormonal, on-demand contraceptive candidate.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005145/en/“As a leader in contraception, we believe it is critically important to bring forward new options for women, especially in the space of non-hormonal contraceptives, a category preferred by many with limited available options,” said Sandra Milligan, M.D., Organon’s head of Research and Development. “Organon is committed to driving innovation across women’s health and collaborating with companies like Cirqle Biomedical to support early science and bring forward new solutions that address th
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (NYSE: OGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $20.00. They now have a "neutral" rating on the stock.MarketBeat
- Organon & Co. (NYSE:OGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- What Makes Organon (OGN) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Organon Reports Results for the First Quarter Ended March 31, 2024Business Wire
- Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store? [Yahoo! Finance]Yahoo! Finance
OGN
Earnings
- 5/2/24 - Beat
OGN
Sec Filings
- 5/3/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/25/24 - Form ARS
- OGN's page on the SEC website